Last updated on May 2020

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Brief description of study

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Detailed Study Description

Global Phase 3, open label long term extension safety study designed to obtain additional safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject has access to tafamidis for ATTR CM via prescription, whichever occurs first.

Clinical Study Identifier: NCT02791230

Find a site near you

Start Over